Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
in short,
myco-anything derives from fungal sources...
endotoxin is primarly from Gram-negative bacteria
Holy,
nice try....
the contamination by bacteria in e. coli based plasmid preparation is not 'gene residue" as you call it, but more so, pieces of what make up the bacterial cell wall and proteins...endotoxin, nasty stuff that can do some bad things to people....
does it mention CYGX?
it has been very clammy the past couple of days....LOL
I hope when the calm breaks it will be to the upside.
Thanks,
well Wawh and Tibbcat? any other interpretations?
TIA
what do the charts say with respect to taking off....is it strictly news that will drive it?
1.02 with a volume of around 168000
1.01 - 1.03 spread
new computer? great....
I had the joy of touring a house for sale that had a functional apple IIe....external 5 1/4 floppy drive and all....
sorry, the temps are in the low 20's...if I widen the window I will freeze....LOL...
OK, Friday it is.....
man, this board is way off topic today....
for some reason, I feel as though tomorrow will be an exciting day....anyone believe with me?
hasn't been here in a while...
My thinking on this is, once the machine is moved, it must be validated, and QA/QC (quality assurance/control) must be documented. If it is moved again, it must be validated again....new QA/QC etc....but it shouldn't matter with respect to temperature, most machines regulate the temperature themselves, and my guess is that their module can also regulate the temperature to optimize the reactions.....
and that is it for the night, have a good one...
may tomorrow we all have the opportunity to retire.....it is a wish...but not a bad one at that
No problem....
The two points I probably agree with you with are
1) they need money/financing
2) they are indeed on their way
I really think in the next month or two the stock is really going to rock...
I don't know what the setup is of the synDNA module, but the one you showed is up to a 20mer (20 nucleotides)....
apparently, the module makes cotton candy....LOL
yes, I am sure the synDNA could manufacture other oligonucleotides as well, but typically, the ones used for basic scientific experiments are much shorter...around 18 - 40 nucltotides in length....these are just used to prime certain reactions, for example, to sequence an unknown piece of DNA.....in short the enzymes that sequence the DNA, or ampllify the DNA (as in PCR, need a jump start, and that is what these primers are
What CYGX is producing is not this type, they are focusing, it appears with the PRs, that the synDNA will be targeted towards therapeutic intervention, be it antisense or antigenic stimulation for generation of active immunity.
IDT makes oligos for sequencing, PCR and other reactions...I don't think they are in the realm of therapeutic oligos....
likewise....even better, I have a feeling this is just a setup for another PR soon...a better one with legs....perhaps some curves, you know, the $$$$ kind? I can only wish...but we all know it is a matter of time.....
Obviously you do not listen to Michael Savage....I advise everyone to listen to his talk show....he tells it like it is....most of the time he is on point
did I not mention $$$$$$ soon?
the dec. prototype PR said "the final version will be mounted on a stainless steel cart and have the capacity to produce up to 10 grams of high-purity DNA in 24 hours"
My guess it that this latest PR is the final mounted version, that is easily moved to whichever location they want....which means transport to other locations (such as companies that buy the thing/technology)....so, my take on the PR is that $$$$$$ is coming soon....and very soon.
what is your take on the last 10 trades, as well as the lack of activity? TIA
another anemic day....please...a PR...with some meat in it?
well, since my Ph.D. focused on Chronic Lymphocytic Leukemia...
Clinical Benefit Analysis of Genasense plus Chemotherapy Reported from Phase 3 Trial in Patients with Chronic Lymphocytic Leukemia
Wednesday February 15, 8:00 am ET
BERKELEY HEIGHTS, N.J., Feb. 15 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) announced the presentation of data regarding clinical benefit from the Company's randomized Phase 3 trial of chemotherapy with or without Genasense (oblimersen sodium) Injection in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The data were presented by Dr. Jef Jones from the M.D. Anderson Cancer Center in Houston, TX at the Tenth Annual International Congress on Hematologic Malignancies in Whistler, British Columbia.
ADVERTISEMENT
In this trial, 241 patients were treated with fludarabine plus cyclophosphamide (Flu/Cy) with or without Genasense. The primary endpoint of the study was to increase the proportion of patients who achieved a complete or nodular partial remission (CR/nPR). The study prospectively defined disease-related symptoms that included fever, night sweats, fatigue, abdominal discomfort or early satiety due to enlargement of liver or spleen, and impaired cosmesis or mobility due to enlarged lymph nodes. "Durable symptom- free benefit" was defined as a period of relief from disease-related symptoms that lasted a minimum of 6 months. "Complete clinical benefit", calculated in patient-months and dating from the onset of CR/nPR to relapse, was defined as the period during which patients were free of all disease, without these symptoms, and with recovered blood counts.
The trial met its primary endpoint: the addition of Genasense increased the proportion of patients who achieved CR/nPR from 7% in the Flu/Cy-only arm to 17% in the Genasense arm (P = 0.025). The duration of CR/nPR was significantly longer in patients treated with Genasense compared with patients who received Flu/Cy only (median = not reached vs. 22 months, respectively; P = 0.03).
At baseline, 83% of patients in the trial were symptomatic. Irrespective of treatment assignment, the proportion of patients who achieved durable symptom-free benefit correlated with the degree of response (CR/nPR = 94%; partial response [PR] = 59%; less than PR = 6%) (P < 0.0001 for CR/nPR vs. others). For both treatment groups, patients who achieved CR/nPR had a median of approximately 11 months longer duration of symptom relief compared with patients whose best response was PR. At last analysis, the duration of complete clinical benefit was 383+ patient-months in the Genasense group compared with 136+ months in the Flu/Cy-only group. Additional safety and efficacy information about this trial can be viewed at the Company's website: http://www.genta.com.
"The analysis from this large, prospective, randomized trial reconfirms what has been intuitively understood by oncologists and hematologists, namely that the achievement of complete remission is highly beneficial for patients with leukemia," said Dr. Loretta M. Itri, Genta's Chief Medical Officer and President, Pharmaceutical Development. "We look forward to improving on these results when we extend the use of Genasense into studies of patients with less advanced disease."
Safety
Grade 3 or Grade 4 adverse events that occurred during treatment or within 30 days from last treatment in an increased percentage of patients in the Genasense group included, but were not limited to, thrombocytopenia, nausea, and intravenous-catheter complications. Adverse events resulted in discontinuation of therapy in an equal percentage of patients in both groups. Nine patients in the Genasense group and 5 patients in the chemotherapy-alone group had adverse events that resulted in death, including two patients in the Genasense group who died from complications associated with tumor lysis and "cytokine release syndrome." Other safety information from the trial can be accessed at: http://www.genta.com/Genta/InvestorRelation/2004/press_20041206.html.
About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The Company has filed a New Drug Application (NDA) to the U.S. Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Genta has also filed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta's small molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com.
This press release contains forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2004.
Thanks
do you know who requested the change and why?
man, this is sure a sluggish day.....
here is one benefit of CYGX technology....
we will never need to get one of these recalls...although our competitors could....HAHAHAHAHAHAHAHA
--------------------------------------------------------------------------------
From: FDA press releases and announcements [mailto:FDANEWSWIRE@LIST.NIH.GOV] On Behalf Of Norwood, Cecilia F
Sent: Monday, February 13, 2006 2:35 PM
To: FDANEWSWIRE@LIST.NIH.GOV
Subject: FDA STATEMENT/FDA-REQUESTED RECALL - CYTOSOL LABORATORIES, INC
FDA STATEMENT Media Inquiries: Catherine McDermott
February 13, 2006 301-827-6242
Consumer Inquiries: 888-INFO-FDA
FDA-Requested Recall - Cytosol Laboratories, Inc.
Product Contains Dangerous Levels of Endotoxin
The U.S. Food and Drug Administration (FDA) today delivered a letter to Cytosol Laboratories, Inc., of Braintree, Mass., to request a recall of all brands and sizes of Balanced Salt Solution (BSS) that the firm manufactures. BSS is a drug used by health professionals to irrigate a patient's eyes, ears, nose and/or throat during a variety of surgical procedures including cataract surgery.
FDA requested the recall because product lots were found to have elevated levels of endotoxin. Endotoxins, also known as pyrogens, are substances found in certain bacteria that cause a wide variety of serious reactions such as fever, shock, changes in blood pressure and in other circulatory functions. FDA has received reports of a serious and potentially irreversible eye injury called Toxic Anterior Segment Syndrome(TASS) which occurs when a contaminant, such as endotoxin, enters the anterior segment of the eye during surgery and causes an inflammatory reaction. FDA has also received complaints relating to injuries in over 300 patients who were given BSS manufactured by Cytosol Laboratories, Inc.
The FDA requests that the company take immediate action to retrieve all inventories of the product, including any existing stock at physician offices and hospitals. An FDA-requested recall is initiated to protect the public health when a product that has been distributed represents a risk of illness or injury and the firm has not initiated a recall of the product. FDA is instructing hospitals, physicians, and consumers to immediately stop using any of these products, quarantine any remaining product, and if no return instructions from Cytosol are received, destroy the product.
An estimated one million units of BSS products were distributed between December 2003 and December 2005. The BSS products subject to the recall order were manufactured by Cytosol Laboratories, Inc. for distribution under three labels:
· "AMO Endosol" distributed by Advanced Medical Optics, Inc. (AMO), Santa Ana, Calif.;
· "Cytosol Ophthalmics" distributed by Cytosol Ophthalmics, Lenoir, NC; and
· "Akorn" distributed by Akorn, Inc., Buffalo Grove, Ill.
Individuals with questions may call FDA at 1-888-463-6332. Any adverse reactions
I really don't know, so someone please answer...
but how do OTCBB shares sell before the bell...I thought it was only the major exchanges that do it?
TIA
sure, I have a sense of humor, when things are done in jest....
I don't think you like A/I, and I don't think your joke was done in jest.....I may be wrong, but I think yoy may be trying to pour some lemon juice into his wounds (so to speak)IMO
Sorry,
I am not a big fan of taunting people...well, percy is another matter....
but, I especially do not approve of attacking family members, or referencing them, even if they do post together..
hey, .98 for the day...up one
well Arnold, you can be happy with that,can't you?
OT or not?
Truth is Subjective
Soren Kierkegaard
1.The difference between an objective and a subjective reflection:
1. A subjective reflection makes its way inwardly in inwardness. Inwardness culminates in passion. The subjective truth is a paradox. A paradox is rooted in its having a relationship to an existing subject.
2. An objective reflection is directed objectively to the truth. Reflection is not focussed upon the relationship, but upon the questions of whether it is the truth to which the knower is related.
3. Take the knowledge of God as an example:
" Objectively, reflection is directed to the problem of whether this object is the true God; subjectively, reflection is directed to the question whether the individual is related to a something in such manner that this relationship is in truth a God-relationship." (p. 95)
1. God is a subject thus only exists for subjectivity:
1. It is impossible to bring God to light objectively.
2. God exists only for subjectivity in inwardness.
3. That one has God is not by virtue of any objective deliberation, but by virture of the infinite passion of inwardness.
2. Objective knowledge and subjective knowledge:
1. Objective knowledge detaches from passion
2. Subjective knowledge counts every delay a deadly peril.
3. Which side has most truth: e.g. The one prays in truth to God though he worships an idol; the other prays in falsely to the true God, and hence worships in fact an idol.
4. Socrates’ problematic manner: If there is an immortality.
1. Three proofs:
2. Socrates himself contributed the passion of infinite.
3. Truth, passion and paradox in Socrates example are for individual.
3. What is said and How it is said:
1. The objective accent falls on WHAT is said.
2. The subjective accent on HOW it is said.
3. In religion, belief makes it objective true but indeed it is that subjective become truth.
" At its maximum this inward "how" is the passion of the infinite, and the passion of the infinite is the truth. But the passion of the infinite is precisely subjectivity and thus subjectivity becomes the truth." "and the subjective ‘how’ constitute the truth." (p.97)
4. A definition of truth and objective uncertainty:
1. A definition: " An objective uncertainty held fast in an appropriation-process of the most passionate inwardness is the truth, the highest truth attainable for an existing individual." (p.98)
2. "The sum of all this is an objective uncertainty."
3. Without risk there is no faith.
5. Conclusion:
" If I am capable of grasping God objectively, I do not believe, but precisely because I cannot do this I must believe. If I wish to preserve myself in faith I must constantly be intent upon holding fast the objective uncertainty."
now Paulness, that is a silly comment
Holy,
glad you are feeling better, we ended up with 18 inches.....it was great shoveling the cars out today....then again, some people would say I was shoveling something today LOL
as far as Jed Clampet.....would you mind if I use the image of Ellie Mae instead? Thanks
so, why don't YOU tell us the terms of PP then?
Oh, but I am sure, you know nothing of this...right?
so, do you think GE had no say into what went into the PR?
how much experience with industry do you have? just a question. TIA
Why attack me?
obviously, you know it all...right? you may want to wake from your nap, open your eyes, and smell the coffee...
and, how may I ask, do you know that your side is correct? You don't...therefore, I believe my point is as valid as yours....actually, I think I would know more about biotech/pharma than you, my friend...XOXO
lawsuit-- name one company without one....as I said...PP was a terrible mistake
No, IND.--for those companies without, most fold...we have kept going...and I forsee a change in this lapse, this year
stock dilution-growiing OTCBB biotech....go figure
bad Pr's-poorly worded in the past....the latest ones, aren't too bad...
no financing---do you really think this is not going to change soon?
failed time lines-- this is a term I refer to as Science Time....yo plan all you want to set deadlines and timelines...never happens...those who have actually been in a lab know this
Etc., etc., etc.-- now please post the positives...
if there are so many negatives, why remain here?
gdepc,
now come on, although I am as RW as most here, even I see PP as a horrible mistake...it should have never happened.....
with that point I agree with you Arnold, but, besides the negatives, there are many positives about the business too....as indicated by the strengthening of their collaborations, Aldevoron, GE, and their SAB and BOD.....they are no longer dealing with sheisters such as the Lane group...and yes, I affiliate everyone with them as sheisters...cheap, dirty, sheisters...but then again, I don't know them...maybe they are upright people...LOL